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Condensation 
Colposcopists are generally supportive of the HPV Test of Cure procedure however concerns 
remain regarding HPV positive cases and risk of false negative HPV results.  
Colposcopists’ experiences of HPV Test of Cure for the follow up of cervical intra-
epithelial neoplasia 
Abstract 
Objective: To survey lead colposcopists in England to explore their views on the recently 
introduced HPV Test of Cure (TOC) following treatment for cervical intra-epithelial 
neoplasia (CIN) and to determine the extent to which it has impacted their clinical practice 
and affected their patients. 
Methods: An online survey was sent to lead colposcopists across England. Questions were 
asked focusing on the clinicians’ confidence in the ability of TOC to guide follow up in 
various clinical scenarios and how the implementation of TOC had changed patient 
management.  
Results: There was a 50% (N=88) response rate. 90% of respondents indicated they were 
happy with the new procedure. In the follow-up questions, 20% indicated they were 
uncomfortable with the procedure when it was applied to women who were CIN2+ with 
incomplete excision at the endocervical margin. Open-ended questions elicited positive 
aspects of TOC including reduced follow-up, increased reassurance for patients and clinicians 
and a faster return to the call-recall system. Negative observations included concerns around 
HPV positive cases, possible false negatives and anxiety in those women who were originally 
subject to the pre-TOC guidelines and were now returned to call-recall “earlier” than 
originally indicated to them. 11% of respondents also indicated they work around the new 
guidelines to some extent. 
Conclusion: Although clinicians are on the whole positive towards the introduction of TOC , 
concerns were raised which centre primarily around those patients with CIN2+ combined 
with positive endocervical margins, issues related to HPV positive cases and the possibility of 
a false negative HPV result. The possibility of patient anxiety due to return to routine 
screening earlier than originally expected was also identified as a concern.  
 
Keywords: Test of Cure, HPV, NHSCSP, cervical screening  
 
 Introduction 
In 2011 the NHS Cervical Screening Programme (NHSCSP) announced the introduction of 
human papillomavirus (HPV) testing for the purposes of triage and test of cure (TOC). This 
was based on evidence from six Sentinel pilot sites. Roll out across England commenced 
from April 2012. Under the old guidelines, once a woman had undergone treatment for 
cervical intra-epithelial neoplasia (CIN) or cervical glandular intra-epithelial neoplasia 
(CGIN), she was followed up for at least ten years with cervical screening at 6 months, 1 year 
and thereafter annually, for 9 years assuming no abnormal results occurred. After ten years 
she was returned to routine recall. Under the new guidelines, 6 months after a woman has 
undergone treatment for CIN the HPV TOC protocol uses high risk HPV (HR-HPV) testing 
to evaluate whether those women require referral for further assessment or whether they can 
be discharged and recalled for screening in 3 years(1). For CGIN two HPV TOCs were 
introduced in May 2014– one at 6 months and another at 18 months after treatment. 
The introduction of TOC has dramatically changed the follow up of CIN with the intention of 
stratifying women’s risk and reducing the number of screening tests performed in the follow 
up cohort. One consequence of the change however, is a greater reliance on colposcopic 
examination in order to exclude high-grade CIN. This creates a difficulty since colposcopy is 
known to miss high-grade disease(2) and in colposcopy following treatment the rate of 
cervical stenosis and unsatisfactory colposcopy increases(3). New technologies, are being 
developed that may have the potential to increase the accuracy of colposcopy in the future.  
However, these techniques are either not approved for use in the NHS Cervical Screening 
Programme or are not mandated as part of the Programme and therefore have not been 
universally adopted by the NHS.  
Cases are emerging of high grade cervical lesions in women who have previously tested 
negative for HR-HPV. Liverani et al for example, found that of 134 CIN 2+ cases, 19 
(14.2%) had tested HR-HPV negative(4), while Cotton et al reported 22% of women with CIN 
2+ as being HPV negative(5). HPV negative cancers have also been reported in the literature. 
One European study reported that HPV testing provides 60-70% greater protection against 
cervical cancer compared to cytology(6). Whilst this may well be true, Liverani observed that 
in that research, “only 11 out of 19 cervical cancers detected over 2.5 years after enrolment, 
were HPV positive at baseline”(7) (p.85). Amongst those deemed by the authors to be 
prevalent by virtue of being diagnosed in the first 2.5 years of the study, 16% were HPV 
negative at baseline. 
With the precise timeline of HPV infection still imperfectly understood(8) and the changes to 
the NHSCSP over the past 4 years introducing a considerable role for HPV testing in the 
screening programme, it would be timely to evaluate the experience of the colposcopists 
working under the new guidelines. The current study was conducted to investigate the impact 
the introduction of the TOC protocol has had on colposcopists and their views on patient 
management.  
Materials and Method 
An electronic survey was conducted of all 191 lead colposcopists across England following 
consultation with the British Society for Colposcopy and Cervical Pathology (BSCCP). An 
email was sent with a link to an online 11 item self-report survey. The only demographic data 
collected was the region in which they worked and when their unit implemented TOC. 
Respondents were then asked to rate how comfortable they were with the TOC protocol in 
different clinical scenarios on a 5 point Likert scale (1-completely uncomfortable, 5-
completely comfortable).  Further items, were open-ended questions, and asked respondents 
to give their views on TOC and to comment on any positive or negative aspects from both the 
point of view of the clinician, patient and service delivery. 
Results 
There was a response rate of 50% (N=88)1. 4% (N=4) adopted the procedure as part of the 
pilot before April 2012, 40% (N=35) adopted it in 2012, 48% (N=42) adopted it in 2013 and 
8% (N=7) adopted it in 2014.   
When asked how comfortable they were with the guidelines, the vast majority (90%, N=79) 
indicated with a score of 4 or 5 that they were comfortable. Only 2% (N=2) indicated that 
they were not comfortable with a score of 1 or 2. 3% (N=3) declined to answer the question 
and 4% (N=4) gave a neutral 3 response.  
                                                          
1 Although the survey was successfully (ie no out of office/bounce back messages received) sent to 176 of the 
191 email addresses, we are aware that some of these will not be current due to the unavailability of revised up 
to date email lists. In addition some clinicians may have been unable to respond due to local IT security 
measures – one clinician contacted the first author to indicate that s/he was unable to access the survey for this 
reason. Therefore the response rate of 50% is likely to be an underestimate. 
Question 4 probed the responses to question three by asking the same question broken down 
by patient classification. The responses are shown in Table 1. 
Respondents were asked what they felt the positive and negative aspects of TOC were. These 
were open ended questions and responses were grouped into categories. Positive aspects of 
the procedure were identified as follows:  less follow-up including attendant reduction in 
non-compliance and reduced patient anxiety associated with repeat medical tests (44%, 
N=37), reassurance for patient and/or clinician (30%, N=25), faster return to call-recall 
system (29%, N=24), evidence-based practice (10%, N=8) and reduced workload/cost saving 
(7%, N=6). There were comments by 10 respondents (N=12) that did not fall into these 
categories. One respondent stated that “Encourages better cooperation between community 
(smearing) and Hospital (colposcopy). Allows a proper community/hospital screening 
program to be developed, used and audited.” Two comments concerned the nature of the test 
– one saying it was easier to get a result, whilst the other commented it was useful where the 
cervix is very scarred. One respondent stated that even when cytology is subsequently 
abnormal at 3 years it can still be treated. Other comments included that the test provides 
additional information (N=2), it could be done by a GP (N=1), after seeing a round of these 
patients, no concerns (N=1) and it identifies the major HPV serotypes implicated in CIN. One 
commented that “It also prompt referrals for the BNC with HGHPV +ve”. 
82% of respondents (N=72) identified negative aspects of TOC. These were categorised as 
follows: concerns around HPV positive cases, including patient anxiety and concerns about 
discharging these patients (28%, N=20); concerns about false negative results (11%, N=8); 
anxiety of women who had been treated under the old guidelines and were returned to 3 
yearly recall “early” (11%, N=8); a feeling that more evidence was needed (8%, N=6); 
concern that something might be missed (7%, N=5); general patient anxiety (7%, N=5); an 
increase in workload/colposcopist responsibility (7%, N=5); issues around explaining HPV to 
patients (6%, N=4); confusion in primary care (6%, N=4); concern about the quality of the 
cervical sample taker/ the screening test missing something (6%, N=4) and the time needed 
for patients/GPs/colposcopists to adjust to the change (4%, N=3). There were 10 
uncategorised comments as follows: “CIN1 not treated and just followed up with smear after 
3 years”; “Does not treat HPV”; “having to explain to women why they have a "new" lesion 
when their next smear is positive... some women are going privately to have another smear 
test, another HPV test...”; “HPV testing is not comprehensive enough; not all high risk 
serotypes are tested for”; “If the loop has come back as negative and MDT has downgraded 
the smear later, we cannot discharge the patient on open exeter without doing a TOC”; “not 
sure about glandulars being included”; “splitting hairs”; “unnecessary colposcopies”; “The 
treatment is for CIN and not for HPV. Patients are still at risk of recurrence, 3 year recall is 
too long”; “very difficult in older women, whom 'normal recall' is no further smears if ~60 
yrs old or more - this is not appropriate as still at risk for ~10-20 yrs, but won't get any more 
smears”. 
Respondents were asked whether they thought the procedure had affected their patients. 64% 
(N=56) indicated that it had, 20% (N=18) indicated that it had not, whilst 16% (N=14) were 
not sure. Those who responded ‘yes’ indicating that they felt it had affected their patients 
were asked to elaborate further.  44 respondents (79%) made positive comments about the 
procedure, 22 (39%) made negative comments and 1 (2%) was neutral. Most of the 
comments repeated the positive and negative aspects of the procedure outlined above, 
however new observations included the fact that it provided an opportunity to educate women 
about HPV (N=1), that it increased patient satisfaction (N=1), “we have gone off protocol for 
a number of older women and picked up an early cancer at 12/12 smear in one” (N=1), “few 
patients request more frequent smears and some of the GP's/colposcopist provide it privately 
which is confusing” (N=1). 
Respondents were asked whether they thought the procedure had affected their clinical 
practice. 85% (N=75) indicated that it had while 15% (N=13) indicated that it had not. All 
respondents were asked to elaborate further and 82% (N=72) chose to do so. 39% (N=28) 
commented on the reduced follow up and/or reduced workload, 18% (N=13) reiterated that 
they had more confidence as a result of the new procedure, 8% (N=6) commented that they 
followed the guidelines or that the guidelines had completely changed, 6% (N=4) indicated it 
either led to a temporary or permanent increase in workload, 6% (N=4) mentioned the role of 
primary care – either stating that women were discharged to primary care or that there were 
concerns about the role of primary care, 3% (N=2) indicated they had concerns about 
discharging older women, and 3% (N=2) indicated that it was hard to follow patients up and 
conduct audit under the new protocol. There were also some uncategorised comments as 
follows: there was reduced follow up in colposcopy previously; it is now easier to discharge 
older women and those with scarring on the cervix; it is harder to confidently discharge 
women, especially those who are HPV positive even with negative colposcopy until there is 
more research data available; less reliance on colposcopy for follow up now; the change in 
follow up has affected counselling; it’s now easier to put stop smoking advice into context; 
having to put faith in histology and accept clinical impressions are not always accurate;  there 
is now a reliance on colposcopy that the “cure” has happened even when TOC is positive 
which is sometimes impossible; patients are being referred back years after treatment who are 
cytology negative, HPV positive; the new protocol enables proper care planning and for the 
introduction of new colposcopic techniques and colposcopes to rationalise care. 
Additionally, 11% (N=8) of respondents indicated that they worked around the guidelines in 
some cases as follows: “We had a HG CIN picked up as we brought patient back in 12 
months, not 3 years as per recommendation in this age group”; “I am very unlikely to report 
colposcopy as "normal" when referred with low-grade HR- HPV or failed TOC as do not 
wish to send to 3 yr recall”; “Increased tendency to biopsy negative cytology and positive hr 
hpv colposcopies”; “Given the poor specificity of colposcopy in  the post treatment cervix I 
use DYSIS® in all failed TOC with a negative smear. - I think this should be considered in 
national guidance”; “greater tendency to take biopsies to confirm no CIN”; “Introduction of 
nurse led test of cure smear clinic. I tried to discharge for community TOC but primary care 
had some anxiety”; “have changed my advice to discharge more women inform my private 
patients of change in NHS policy, so offer them the choice of follow up in 3 years or remain 
under annual review”; “I may use my clinical judgement to decide the indication for an 
earlier smear”.  
Finally there was an open ended question inviting any further comments. Most of these 
repeated points identified above. Additional comments included a description of a specific 
incident, a suggestion that TOC should be test of “clearance” rather than cure, confusion 
because some patients are in TOC whilst some are not, a suggestion that it should be 
extended to other areas such as vault smears and an observation that there are lots of centres 
with too much follow up in colposcopy. Lastly, there were two questions included in the 
responses in relation to other topics outside the scope of this study. 
Comment 
At first glance, the responses to question 3 suggest that the vast majority of colposcopists are 
happy with the new TOC protocol however, further probing reveals some disquiet with the 
procedure in certain patient groups. Where patients with CIN2+ have incomplete excision on 
the endocervical margin, 20% of clinicians are not satisfied while another 20% are neither 
satisfied nor dissatisfied. This contrasts with the 100% of colposopists who were satisfied 
with using TOC in patients with complete excision of CIN1 and is likely to reflect the clinical 
uncertainty associated with those patients which would previously have been monitored over 
10 years. Some of this disquiet may well stem from previous research9 that proposed that 
“careful follow-up is essential for at least 10 years after conservative treatment of CIN” 
(p978). However this research was published prior to current knowledge about HPV and it 
could be argued that HPV TOC enables efficient selection for follow-up of those women who 
remain at risk post-operatively whilst reassuring those who are not10.  
There are considerable advantages to the new protocols as colposcopists identified including 
patient reassurance, speedy return to the call-recall system and cost savings. The latter is one 
of the drivers for introducing HPV TOC for cytologically negative women. Recent modelling 
suggests that there would be a cost saving of £9388 per 1000 women compared to cytology 
only and that an additional 8.4 CIN3+ cases would be averted(11). However, despite 90% of 
colposcopists indicating their satisfaction with the procedure in question 3, when offered the 
opportunity to identify any negatives about the procedure, 82% chose to do so including 
clinicians from the original pilot sites as well those from sites that rolled out the procedure 
later. The most sizeable area mentioned was patient and clinical concerns about HPV positive 
results. Other negatives raised were general patient anxiety, or anxiety as a result of from 
moving from the old guidelines to the new ones, concerns around false negative results and a 
fear that something might be missed. In the changes to clinical practice follow-up open ended 
question, some clinicians indicated that they were working around the guidelines to an extent 
to combat colposcopy negative, HPV positive cases.  It is not possible from this study to 
ascertain if this is on an individual case basis which should involve an MDT discussion, or a 
routine approach; routinely disregarding the national guidelines has the potential to 
undermine the TOC protocol and its implementation rationale. 
Several respondents suggested that further evidence was needed before they could be fully 
confident and it may well be that confidence in HPV TOC will increase or conversely may 
decrease over time as more evidence is accrued. Full evidence on the effectiveness of TOC in 
routine practice across the NHS Cervical Screening Programme will only become evident 
with time and therefore it is imperative that there is accurate, prospective data collection, 
ideally at a population level, in order to ensure the guidelines appropriately reflect the 
available evidence. 
This study provides important evidence about the responses of clinicians to this significant 
change in national screening guidelines that affected clinical practice.  The findings of this 
study should be taken into account in the event of future major changes in the Cervical 
Screening Programme in particular in relation to the training and evidence required for 
clinical staff to be able to confidently support the changes when rolled out in practice. 
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Table 1: How comfortable respondents were with the guidelines by patient classification. 
Patient 
classification 
Comfortable (4 or 
5) 
Neutral (3) Uncomfortable (1 or 
2) 
CIN1 complete 
excision 
100% (N=88) 0 0 
CIN2+ complete 
excision 
98% (N=86) 1% (N=1) 1% (N=1) 
CIN1 incomplete 
excision at the 
endocervical 
margina,b 
85% (N=75) 5% (N=4) 9% (N=8) 
CIN2+ incomplete 
excision at the 
endocervical 
marginb 
59% (N=52) 20% (N=18) 20% (N=18) 
CIN1 incomplete 
excision at the 
ectocervical margin 
93% (N=82) 7% (N=6) 0 
CIN2+ incomplete 
excision at the 
ectocervical margin 
83% (N=73) 11% (N=10) 6% (N=5) 
a1 respondent declined to answer this question 
bWhere numbers do not total 100%, this is due to rounding errors 
 
